Beryl Drugs

Why is Beryl Drugs Ltd falling/rising?

As of 30-Aug, Beryl Drugs Ltd's stock price has risen to 22.92, up 2.96%, driven by strong sector performance and positive momentum above moving averages, despite a slight decline in delivery volume.

As of 30-Aug, Beryl Drugs Ltd is experiencing a rise in its stock price, currently at 22.92, with a change of 0.66 (2.96%) upwards. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 2.37% today, indicating strong relative performance. Additionally, Beryl Drugs has been on a positive trajectory, gaining for the last two days and achieving a total return of 3.57% during this period.<BR><BR>Moreover, the stock is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests bullish momentum. Despite a slight decline in investor participation, as evidenced by a 3.9% drop in delivery volume compared to the 5-day average, the overall liquidity remains sufficient for trading activities.<BR><BR>In summary, the combination of recent gains, strong performance relative to the sector, and favorable moving average positioning contributes to the rising stock price of Beryl Drugs Ltd.

Which are the latest news on Beryl Drugs?

Should I buy, sell or hold Beryl Drugs Ltd?

Who are in the management team of Beryl Drugs?

The management team of Beryl Drugs includes Sanjay Sethi (Executive Director and Managing Director), Sudhir Sethi (Chairman), Abhinav Naik, and Shreya Saraf (both Independent Non-Executive Directors).

The management team of Beryl Drugs includes the following individuals:<BR><BR>1. **Sanjay Sethi** - Executive Director, Managing Director, and Promoter<BR>2. **Sudhir Sethi** - Chairman and Non-Executive Director<BR>3. **Abhinav Naik** - Independent Non-Executive Director<BR>4. **Shreya Saraf** - Independent Non-Executive Director<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

What does Beryl Drugs do?

Beryl Drugs Ltd manufactures, sells, and exports branded and generic pharmaceuticals. As of June 2026, it reported net sales of 7 Cr and a market cap of INR 11 Cr.

Overview:<BR>Beryl Drugs Ltd is engaged in the manufacture, sale, and export of branded and generic pharmaceutical formulations within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History:<BR>Beryl Drugs Limited was incorporated on August 24, 1993, and acquired the running business of M/s Flora and Fauna Remedies Limited on December 15, 1993. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 7 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Jun 2026)<BR>- Market-cap: INR 11 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 18.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.22<BR>- Return on Equity: 6.28%<BR>- Price to Book: 1.20<BR><BR>Contact Details:<BR>Address: 133 Kanchan Bag, Indore Madhya Pradesh: 452001<BR>Tel: 91-731-25076375/3046366<BR>Email: beryldrugs25@yahoo.com<BR>Website: http://www.beryldurgs.com

Who are the peers of the Beryl Drugs?

Beryl Drugs' peers include Dipna Pharmachem, Unjha Formul, Starsource Multi, Ortin Global, Vivanza Biosci, Ganga Pharma, Decipher Labs, Brawn Biotech, and Saroja Pharma In. Unjha Formul leads in 1-year return at 9.49%, while Beryl Drugs has a return of 19.98%, outperforming most peers except Unjha Formul.

Peers: The peers of Beryl Drugs are Dipna Pharmachem, Unjha Formul., Starsource Multi, Ortin Global, Vivanza Biosci., Ganga Pharma., Decipher Labs, Brawn Biotech, and Saroja Pharma In.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dipna Pharmachem, while Average management risk is found at Unjha Formul. and Saroja Pharma In, and the rest have Below Average management risk. For growth, Excellent growth is seen at Dipna Pharmachem, Average growth at Vivanza Biosci., and Below Average growth at Unjha Formul., Ortin Global, Ganga Pharma., Decipher Labs, Brawn Biotech, and the rest. Regarding capital structure, Good capital structure is noted at Unjha Formul., while Average capital structure is found at Ganga Pharma., and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Unjha Formul. at 9.49%, while the peer with the lowest is Dipna Pharmachem at -74.53%. Beryl Drugs has a 1-year return of 19.98%, which is significantly higher than all peers except Unjha Formul. Additionally, several peers, including Decipher Labs, Brawn Biotech, and Vivanza Biosci., have negative six-month returns.

How big is Beryl Drugs?

As of 14th August, Beryl Drugs Ltd has a market capitalization of 12.00 Cr, with recent net sales of 21.33 Cr and a net profit of 0.62 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Beryl Drugs Ltd has a market capitalization of 12.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 21.33 Cr, while the sum of Net Profit for the same period is 0.62 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 9.50 Cr, and Total Assets amount to 15.95 Cr.

When is the next results date for Beryl Drugs Ltd?

The next results date for Beryl Drugs Ltd is 11 August 2026.

The next results date for Beryl Drugs Ltd is scheduled for 11 August 2026.

Are Beryl Drugs Ltd latest results good or bad?

Beryl Drugs Ltd's latest Q4 FY26 results show a positive turnaround with a net profit of ₹0.56 crores and a 35.71% revenue increase, indicating improved operational efficiency. However, concerns about the company's historical volatility and ongoing challenges suggest that caution is warranted despite this strong quarter.

Beryl Drugs Ltd's latest results for Q4 FY26 show a significant turnaround, indicating a positive trajectory in certain areas. The company reported a net profit of ₹0.56 crores, marking a return to profitability after a previous loss of ₹0.17 crores in the prior quarter. Additionally, revenue increased by 35.71% quarter-on-quarter and 29.22% year-on-year, reaching ₹5.13 crores, which reflects a strong recovery.<BR><BR>The operating margin also improved dramatically to 26.12%, the highest in seven quarters, suggesting enhanced operational efficiency. Furthermore, the profit after tax (PAT) margin rose to 10.92%, up from negative figures in the previous quarter.<BR><BR>However, while these results are encouraging, they come with caveats. The company has exhibited significant volatility in its financial performance over the past several quarters, raising concerns about sustainability. The full-year performance remains troubling, with a decline in annual revenue and persistent challenges in profitability.<BR><BR>Overall, while the latest quarterly results are good in isolation, they highlight a dramatic recovery that must be viewed within the context of the company's historical volatility and ongoing operational challenges. Investors should remain cautious, as a single strong quarter does not necessarily indicate a definitive turnaround.

How has been the historical performance of Beryl Drugs?

Beryl Drugs' historical performance shows fluctuating financial metrics, with net sales peaking at 26.89 Cr in Mar'23 but declining to 21.15 Cr by Mar'25, while total operating income also fell from 27.16 Cr to 22.56 Cr in the same period. Despite a decrease in profits and total assets, cash flow from operating activities improved to 2.00 Cr in Mar'25.

Answer:<BR>The historical performance of Beryl Drugs shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Beryl Drugs' net sales peaked at 26.89 Cr in Mar'23 but declined to 21.15 Cr by Mar'25. Other operating income increased from 0.00 Cr in Mar'19 to 1.41 Cr in Mar'25, contributing to a total operating income that reached a high of 27.16 Cr in Mar'23 before falling to 22.56 Cr in Mar'25. The raw material cost also saw a decline from 14.23 Cr in Mar'23 to 11.12 Cr in Mar'25, while total expenditure decreased from 24.95 Cr in Mar'23 to 19.91 Cr in Mar'25. Operating profit (PBDIT) slightly decreased from 2.68 Cr in Mar'24 to 2.65 Cr in Mar'25, with profit before tax showing a decline from 1.01 Cr in Mar'24 to 0.87 Cr in Mar'25. Profit after tax also decreased from 0.77 Cr in Mar'24 to 0.58 Cr in Mar'25. The company's total assets decreased from 17.39 Cr in Mar'23 to 15.95 Cr in Mar'25, while total liabilities also fell from 17.39 Cr to 15.95 Cr during the same period. Cash flow from operating activities improved to 2.00 Cr in Mar'25, contrasting with previous years where it was zero. Overall, Beryl Drugs has experienced both growth and decline in various financial aspects, reflecting a complex performance trajectory.

Is Beryl Drugs overvalued or undervalued?

As of September 2, 2025, Beryl Drugs is considered very attractive with a PE ratio of 12.71 and an EV to EBITDA of 7.30, indicating it is undervalued compared to peers like Sun Pharma and Divi's Lab, despite a challenging year-to-date performance of -29.05%, as it has achieved a 3-year return of 168.59%, significantly outperforming the Sensex.

As of 2 September 2025, Beryl Drugs has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, with a PE ratio of 12.71, an EV to EBITDA of 7.30, and a ROCE of 10.96%. In comparison, its peers exhibit significantly higher valuations, such as Sun Pharma with a PE ratio of 32.69 and Divi's Lab at 70.48, indicating that Beryl Drugs offers a more favorable investment opportunity relative to its competitors.<BR><BR>Despite a challenging year-to-date performance of -29.05%, Beryl Drugs has shown resilience with a 3-year return of 168.59%, significantly outperforming the Sensex's 36.32% return during the same period. This suggests that the market may not fully recognize the company's potential, further supporting the conclusion that it is undervalued.

Who are the top shareholders of the Beryl Drugs?

The top shareholders of Beryl Drugs include promoter Sanjay Sethi with 10.88% and public shareholder Samir Narendra Gupta with 4%. Individual investors collectively hold 68.69%, with no institutional holdings or pledged shares reported.

The top shareholders of Beryl Drugs include Sanjay Sethi, who is the promoter with the highest holding at 10.88%. The highest public shareholder is Samir Narendra Gupta, holding 4%. Additionally, individual investors collectively hold a significant portion of the company at 68.69%. There are no institutional holdings or pledged promoter shares reported.

What is the technical trend for Beryl Drugs?

As of February 21, 2025, Beryl Drugs is in a bearish trend with moderate strength, indicated by bearish MACD, moving averages, and KST, alongside mildly bearish Bollinger Bands and Dow Theory signals.

As of 21 February 2025, the technical trend for Beryl Drugs has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this assessment include a bearish MACD on the weekly chart, bearish moving averages on the daily timeframe, and a bearish KST on the weekly. Additionally, Bollinger Bands are indicating a mildly bearish trend on both weekly and monthly charts. The Dow Theory shows a mildly bearish stance on the weekly but no trend on the monthly, further supporting the bearish outlook.

Has Beryl Drugs declared dividend?

No Dividend History Available